News | November 12, 2021
Solara Active Pharma Sciences PAT slides to Rs 29.71 cr in Q2FY22
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
Glycopyrrolate injection can also be used in adults as an adjunctive therapy for the treatment of gastrointestinal ulcer when a rapid effect is desired or when oral medication is not tolerated
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
Filing marks first protein-based vaccine submitted to MHRA for authorization
The collaboration aims to deliver greater insights to the oncology fraternity, predict patient therapy responses and enable therapy selection resulting in optimal treatment outcomes.
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
The revised deal involves a cash consideration only as against the earlier proposal of cash and equity
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
Subscribe To Our Newsletter & Stay Updated
